GI pharmaceutical company closes $60M fundraising round

What you should know:

1. RTW Investments and Perceptive Advisors co-led the fund, with Osage University Partners and entities affiliated with Paul Manning contributing.

2. The company will use the funds to support the development of its ulcerative colitis and Crohn’s disease drug candidate, as well as additional pipeline candidates.

3. RTW Investments and Perceptive Advisors each appointed a person to Landos’ board as a result of the investment.

More articles on surgery centers:
10 ASC industry key notes
Pennsylvania ASC plans to take Horizon insurance
7 ASCs, surgeons introducing robotics in 2019

Next Up in GI & Endoscopy

ConMed to end its GI product lines

Medical device company and surgical equipment manufacturer ConMed plans to exit its gastroenterology product lines. ConMed’s gastroenterology segment is projected…

Gastroenterologists find success in using AI for surveillance colonoscopy intervals

Gastroenterologists at the University of Miami Miller School of Medicine and the University of Pennsylvania Perelman School of Medicine have…

The titans of gastroenterology M&A

Here are three major GI groups leading gastroenterology practice acquisitions and ASC growth: GI Alliance Southlake, Texas-based GI Alliance is…

How AdventHealth unlocked $24M in 4 months

Next Up in GI & Endoscopy

ConMed to end its GI product lines

Gastroenterologists find success in using AI for surveillance colonoscopy intervals

The titans of gastroenterology M&A

Join the 40,000+ ASC leaders who start their day with Becker's